TSC 204
Alternative Names: TSC-204; TSC-204-A0201; TSC-204-C07; TSC-204-C0702Latest Information Update: 16 Dec 2025
At a glance
- Originator TScan Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 12 Nov 2025 TScan Therapeutics paused enrollment a phase I PLEXI-T trial in Solid tumours in the US due to focus on preclinical development of in vivo engineering to treat patients with solid tumors (NCT05973487)
- 06 Mar 2024 Tscan Therapeutics plans a phase I trial for Solid tumours in the first quarter of 2024
- 06 Mar 2024 US FDA approves IND application for TSC 204 for TSC-204-A0101 in Solid tumours